Posts

Posted on

Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 Per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock

Company Elects to Defer Monthly Cash Dividend on 10.00% Series E Preferred Stock

LAS VEGAS, Dec. 20, 2024 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that its Board of Directors (the “Board”) has declared a monthly cash dividend of $0.2708333 per share of the Company’s outstanding 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”). The record date for this dividend is December 31, 2024, and the payment date is Friday, January 10, 2025.

Link to NYSE quote for the Company’s Series D Preferred Stock: https://www.nyse.com/quote/XASE:GPUSpD

The Company further announced today that the Board has elected not to declare a monthly cash dividend on its outstanding 10.00% Series E Cumulative Redeemable Perpetual Preferred Stock (the “Series E Preferred Stock”) for the month ending December 31, 2024. The certificate of designations for the Series E Preferred Stock permits the Company to defer up to 12 consecutive monthly dividend payments on the Series E Preferred Stock without such deferrals being considered missed (a “Permitted Deferral”). The Company notes that the dividend is a cumulative dividend that accrues for payment in the future.

Hyperscale Executive Chairman Milton “Todd” Ault III stated, “The Company remains committed to paying consistent dividends as evidenced by the Company never missing a dividend payment on the Series D Preferred Stock since its inception in June 2022. The just-declared dividend payment for the Series D Preferred Stock will be the 30th consecutive dividend payment. As the Series E Preferred Stock was just issued to stockholders as a dividend, the Company always anticipated electing to defer this month’s dividend, which is why Permitted Deferrals were included in the certificate of designations. We anticipate declaring and paying out the deferred dividend payment sometime in 2025.”

For more information on Hyperscale Data and its subsidiaries, Hyperscale Data recommends that stockholders, investors, and any other interested parties read Hyperscale Data’s public filings and press releases available under the Investor Relations section at hyperscaledata.com or available at www.sec.gov.

About Hyperscale Data, Inc.

Hyperscale Data is transitioning from a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact to becoming solely an owner and operator of data centers to support high performance computing services. Through its wholly and majority-owned subsidiaries and strategic investments, Hyperscale Data owns and operates a data center at which it mines digital assets and offers colocation and hosting services for the emerging artificial intelligence ecosystems and other industries. It also provides, through its wholly owned subsidiary, Ault Capital Group, Inc., mission-critical products that support a diverse range of industries, including an artificial intelligence software platform, social gaming platform, equipment rental services, defense/aerospace, industrial, automotive, medical/biopharma and hotel operations. In addition, Hyperscale Data is actively engaged in private credit and structured finance through a licensed lending subsidiary. Hyperscale Data’s headquarters are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141; Hyperscale Data, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties.

Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8- K. All filings are available at www.sec.gov and on the Company’s website at www.hyperscaledata.com.

Hyperscale Data Investor Contact:

[email protected] or 1-888-753-2235



Posted on

Vertiv Acquires Centrifugal Chiller Technology to Broaden its Global Solutions Portfolio in Support of High-Performance Compute and AI

Vertiv Acquires Centrifugal Chiller Technology to Broaden its Global Solutions Portfolio in Support of High-Performance Compute and AI

China-based company BSE specializes in both water-cooled and air-cooled systems with up to 5.5 MW of cooling capacity, as well as heat recovery and reuse solutions

COLUMBUS, Ohio–(BUSINESS WIRE)–
Vertiv (NYSE: VRT), a global provider of critical digital infrastructure and continuity solutions, today announced the acquisition by its Chinese subsidiary of certain assets and technologies of BiXin Energy Technology (Suzhou) Co., Ltd (BSE), a manufacturer of chillers, heat pumps, heat-recovery solutions and air-handling units. Focused on expanding the Vertiv chiller family, the acquisition strengthens Vertiv’s portfolio of critical technologies and solutions in support of high-performance compute and AI applications globally. Founded in 2010, BSE brings to Vertiv an established and field-proven presence in the China market and other Asian regions, along with industry patents, advanced technology solutions and strong research and development capabilities that will reinforce Vertiv’s global offering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241219522857/en/

Vertiv™ air-cooled chiller unit (Photo: Business Wire)

Vertiv™ air-cooled chiller unit (Photo: Business Wire)

BSE’s core product offerings include oil-free, magnetic-bearing centrifugal water-cooled and air-cooled chillers incorporating pumped-refrigerant-economization technology, with cooling capacities of up to 5.5 MW. BSE is a leader in the Asia region on centrifugal technology, which is designed to provide high efficiency, low maintenance, quiet operation and high reliability.

“This acquisition supports our capital allocation strategy, which includes adding technologies that are early in the maturity curve to our portfolio,” said Giordano Albertazzi, Chief Executive Officer, Vertiv. “BSE’s solutions and technologies complement and reinforce Vertiv’s existing chiller portfolio and will assist us in addressing growing air and liquid cooling demand to support high-performance compute and AI. Vertiv has the most complete critical digital infrastructure portfolio and BSE further strengthens our technology offerings that we can provide to customers globally.”

Since early 2024, Vertiv has partnered with BSE to manufacture Vertiv-branded products for existing customers in China and throughout Asia. BSE is an Air Conditioning, Heating, Refrigeration Institute (AHRI) certified test facility, a China Refrigeration and Air-Conditioning Industry Association (CRAA) member and a China High and New-Technology Enterprise. Its products carry the AHRI-certified and CRAA-certified product labels. The combination of engineering, test and technology expertise in centrifugal chillers is complementary to Vertiv’s global chiller product portfolio.

“We’ve enjoyed an outstanding partnership with Vertiv and look forward to becoming a part of the company,” said York Zha, BSE’s CEO. “We’re excited to combine our portfolio with Vertiv’s to deliver a highly efficient and reliable offering of chiller and heat-recovery and reuse solutions for data center customers globally.”

About Vertiv

Vertiv (NYSE: VRT) brings together hardware, software, analytics and ongoing services to enable its customers’ vital applications to run continuously, perform optimally and grow with their business needs. Vertiv solves the most important challenges facing today’s data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Headquartered in Westerville, Ohio, USA, Vertiv does business in more than 130 countries. For more information, and for the latest news and content from Vertiv, visit Vertiv.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27 of the Securities Act, and Section 21E of the Securities Exchange Act. These statements are only a prediction. Actual events or results may differ materially from those in the forward-looking statements set forth herein. Readers are referred to Vertiv’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q for a discussion of these and other important risk factors concerning Vertiv and its operations. Vertiv is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Sara Steindorf – Fleishman Hillard

[email protected]

KEYWORDS: Ohio China United States North America Asia Pacific

INDUSTRY KEYWORDS: Software Data Analytics Hardware Artificial Intelligence Data Management Professional Services Technology Apps/Applications

MEDIA:

Logo
Logo
Photo
Photo
Vertiv™ air-cooled chiller unit (Photo: Business Wire)
Posted on

Cable One Amends Mega Broadband Strategic Partnership

Cable One Amends Mega Broadband Strategic Partnership

Amended partnership agreement provides enhanced timing flexibility for path to full ownership of MBI

PHOENIX–(BUSINESS WIRE)–
Cable One, Inc. (NYSE: CABO) (“Cable One”) announced today that it has amended the terms of its strategic investment in Mega Broadband Investments Holdings LLC (“MBI”) to provide enhanced timing flexibility for Cable One’s potential acquisition of full ownership of MBI. Cable One currently owns a 45% stake in MBI, and affiliates of GTCR LLC (“GTCR”) and MBI management own the balance of MBI. The amendments provide Cable One with enhanced ability to control the timing for acquiring the 55% interest it does not currently own pursuant to the put right held by GTCR, with any such acquisition to occur no earlier than October 1, 2026 unless Cable One elects to close the transaction at an earlier date.

“Our strategic investment in MBI reflects our commitment to provide rural America with reliable high-speed internet service,” said Julie Laulis, President and CEO of Cable One. “We continue to value MBI for all the reasons that first drew us to them: their commitment to providing leading broadband services in rural markets, their track record of strong growth and impressive potential for future growth, as well as their exceptional team.”

Todd Koetje, CFO of Cable One, said, “We are pleased with the terms provided by the partnership agreement amendments, which we believe will further enhance Cable One’s overall capital structure flexibility, as our net leverage ratio is now expected to peak in the fourth quarter of 2024 following this transaction.”

MBI is a leading provider of broadband services across the Southeast, Northwest and Mid-South United States and offers an extensive range of broadband, fiber connectivity, cable television and voice services for commercial and residential customers under the Vyve Broadband brand. MBI’s total revenues for the 12 months ended September 30, 2024 were approximately $320 million, with approximately 226,000 residential and business data customers across a network footprint with approximately 674,000 passings as of September 30, 2024.

Transaction Details

As part of the amended partnership agreement, Cable One paid $250 million to the other MBI equity holders, and those same other equity holders also received the proceeds from $100 million of new MBI debt. The combined $350 million of payments will reduce the purchase price payable by Cable One on a dollar-for-dollar basis for the 55% interest in MBI it does not currently own as described in more detail below. Concurrently, new arrangements were put in place to provide timing flexibility for Cable One’s potential acquisition of full ownership of MBI:

  • Cable One has a new option to call the 55% of MBI it does not already own, exercisable starting in the third quarter of 2025;

  • GTCR’s existing option to put to Cable One the 55% of MBI it does not already own has been adjusted to defer the closing of any put exercise to no earlier than October 1, 2026 (unless Cable One elects to cause the closing to occur earlier);

  • If the closing of a put option exercise or call option exercise occurs prior to October 1, 2026, the purchase price payable by Cable One will be discounted at a rate of 12% for the period from October 1, 2026 to the closing date.

The purchase price payable by Cable One at the closing of a call option exercise or put option exercise will be calculated under a formula based on (i) a multiple of MBI’s adjusted earnings before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2025 and (ii) MBI’s total net indebtedness (disregarding the impact of the $100 million of new MBI debt described above), less a dollar-for-dollar reduction for both the upfront payment and the proceeds from the new MBI debt received by the other MBI equity holders as part of the amendment.

Based on currently available information, if the closing of a call option exercise or put option exercise occurs on October 1, 2026, Cable One estimates that (i) the purchase price payable by Cable One will range between approximately $410 million and $550 million and (ii) MBI’s total net indebtedness that will be outstanding at the time it becomes wholly-owned by Cable One will be approximately $845 million to $895 million. These estimates are based on MBI’s past performance and current forecasts and are subject to numerous assumptions and risks including, without limitation, factors that could impact MBI’s performance, such as competition, economic conditions, operating performance and other factors referenced below under “Cautionary Statement Regarding Forward-Looking Statements”. If any of those underlying assumptions prove incorrect, or if any of those risks materialize, the actual purchase price payable by Cable One upon a call option exercise or put option exercise and the amount of MBI’s indebtedness outstanding at that time may differ from the estimated amounts described above.

Cravath, Swaine & Moore LLP acted as legal advisor, and Centerview Partners LLC acted as financial advisor to Cable One on the amended partnership transaction.

About Cable One

Cable One, Inc. (NYSE:CABO) is a leading broadband communications provider delivering exceptional service and enabling more than 1 million residential and business customers across 24 states to thrive and stay connected to what matters most. Through Sparklight® and the associated Cable One family of brands, we’re not just shaping the future of connectivity–we’re transforming it with a commitment to innovation, reliability and customer experience at our core.

Our robust infrastructure and cutting-edge technology don’t just keep our customers connected; they help drive progress in education, business and everyday life. We’re dedicated to bridging the digital divide, empowering our communities and fostering a more connected world. When our customers choose Cable One, they are choosing a team that is always working for them–one that believes in the relentless pursuit of reliability, because being a trusted neighbor isn’t just what we do–it’s who we are.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those expressed or implied by these statements. You can generally identify forward-looking statements by the words “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “objective,” “outlook,” “plan,” “potential,” “predict,” “projection,” “seek,” “should,” “target,” “trend,” “will,” “would” or the negative version of these words or other comparable words. Any statements regarding expectations and opportunities related to MBI, Cable One’s future net leverage ratio, the related put right and call right, the amounts payable upon the exercise of those rights and any other statements that are not historical facts are forward-looking statements. Such forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include, but are not limited to, the factors described under “Risk Factors” in Cable One’s Amendment No.1 to its Annual Report on Form 10-K/A for the period ended December 31, 2023 and its other filings with the Securities and Exchange Commission, and uncertainties, assumptions and changes in circumstances that may cause Cable One’s and/or MBI’s actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. Each forward-looking statement contained herein speaks only as of the date of this press release, and Cable One undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

Trish Niemann

Vice President, Communications Strategy

[email protected]

Todd Koetje

CFO

[email protected]

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Networks Internet Technology Carriers and Services Telecommunications

MEDIA:

Logo
Logo
Posted on

Announcement of Intention to Delist American Depositary Shares From the New York Stock Exchange and Subsequent Arrangements

Announcement of Intention to Delist American Depositary Shares From the New York Stock Exchange and Subsequent Arrangements

ENVIGADO, Colombia–(BUSINESS WIRE)–
Almacenes Éxito S.A. (BVC: EXITO; NYSE: EXTO; B3: EXCO32) (“Éxito” or “the Company”) informs its shareholders and the market in general that today its Board of Directors approved the commencement of the process to: (i) voluntarily delist its American depositary shares (“ADSs”), each representing eight common shares of the Company, from the New York Stock Exchange (the “NYSE”); and (ii) deregister the Company’s securitiesunder the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), after taking into account a number of considerations, including the Company’s current reduced free float (13.2%), which is distributed between Colombia with 1.6%, the United States with 1.6% and Brazil with 10%, which represents an opportunity for the Company to look forward to a more efficient structure for all stakeholders.

The Company’s decision to embark on a process to delist and deregister its securities is not driven by costs or concerns regarding compliance with the requirements and regulations required to maintain a listing on the NYSE or the other stock exchanges where it has a presence, but rather the proposal is focused on facilitating a more efficient structure, concentrating its float in the Colombian market, which is its natural market, to increase the liquidity of its stock and maximize the return to all its shareholders.

The Company intends to file a Form 25 with the United States Securities and Exchange Commission (the “SEC”) on December 30, 2024 to delist its ADSs from the NYSE. The delisting of the ADSs from the NYSE is expected to become effective ten days thereafter. The last day of trading of the ADSs on the NYSE is expected to be on or after January 9, 2025. From and after that date, the ADSs of the Company will no longer be listed and traded on the NYSE.

Today the Company has also directed JPMorgan Chase Bank N.A. (“JPMorgan”) to terminate its ADS program after delisting its ADSs from the NYSE. Consequently, and in accordance with the terms of the deposit agreement and the ADSs, JPMorgan will provide a notice of termination to all ADS holders containing relevant information for ADS holders regarding required actions. The effective date of the termination of the ADS program will be January 21st, 2025. Between the delisting of the ADSs from the NYSE and the termination of the ADS program, the ADSs may continue to be traded over-the-counter. After the termination of the ADS program, the Company does not intend to seek a listing or registration of its securities on a U.S. national securities exchange or for their quotation in a quotation medium in the United States. However, the Company´s common shares will continue to be traded on The Stock Exchange of Colombia – Bolsa de Valores de Colombia (the “BVC”). The Company will also continue to comply with its information disclosure and other obligations as a listed issuer under the relevant rules of the BVC as well as other applicable laws and regulations. The Company is currently evaluating its performance as a foreign private issuer in Brazil to determine the alternatives for its sponsored Brazilian depositary share (BDR) program in Brazil and will maintain its shareholders and the market in general informed of any developments in that regard.

Once the delisting has become effective and the criteria for deregistration have been satisfied, the Company intends to file a Form 15F with the SEC to deregister the Company’s securities under the Exchange Act. Thereafter, all of the Company’s reporting obligations under the Exchange Act will be suspended unless the Form 15F is subsequently withdrawn or denied. Deregistration and termination of the Company’s reporting obligations under the Exchange Act are expected to become effective 90 days after its filing of Form 15F. Once the Form 15F is filed, the Company will publish the information required under Rule 12g3-2(b) of the Exchange Act on its website, https://www.grupoexito.com.co. Until such time, and for the time being, the Company will continue to be registered under Exchange Act and will continue to comply with its reporting obligations under the Exchange Act.

The Company reserves its rights in all respects, for any reason, to delay or withdraw the aforementioned filings prior to their effectiveness and will issue any further announcement if required under the listing rules or other applicable laws and regulations.

Important Notice Regarding Forward-Looking Statements:

This press release contains forward-looking statements. These statements are statements that are not historical facts, and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

Additional Information:

This press release is not an offer of securities for sale in the United States, Colombia, Brazil or elsewhere. It is merely intended for information purposes, under the terms of the applicable laws and regulations, and shall not, in any circumstances, be deemed or considered as an investment recommendation, an offer for sale, or a solicitation or offer for acquisition of securities of the Company.

For further information, please contact:

Éxito Investor Relations Department

Email: [email protected]

Telephone: +57 (604) 604 9696 ext: 306560

KEYWORDS: Latin America North America United States South America Colombia

INDUSTRY KEYWORDS: Retail Professional Services Other Retail Finance

MEDIA:

Posted on

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

~ PEDMARQSI®
 (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~

~ Data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal) and the Clinical Oncology Group (COG) Protocol ACCL0431, demonstrated an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients treated with cisplatin and sodium thiosulfate vs. those treated with cisplatin alone ~

~ There is a clear unmet need for the prevention of hearing loss caused by cisplatin and until now, there have been no preventative pharmacological interventions available, despite the significant lifelong impact hearing loss has on cancer patients ~

RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence (NICE) recommending PEDMARQSI for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors.

PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localized, non-metastatic solid tumors. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia, and New Zealand.

“Securing access to PEDMARQSI is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,” said Jeff Hackman, chief executive officer and director of Fennec Pharmaceuticals. “We congratulate Norgine on their collaboration with NICE to reach this important agreement that recognizes the value of ototoxicity intervention as part of the cancer treatment journey.”

Under the terms of the previously announced exclusive licensing agreement with Norgine, Fennec received approximately $43 million in an upfront payment and will receive up to approximately $230 million in additional commercial and regulatory milestone payments along with double-digit tiered royalties on net sales of PEDMARQSI starting in the mid-teens and growing to the mid-twenties.

About Cisplatin-Induced Ototoxicity

Cisplatin and other platinum compounds are essential chemotherapeutic agents for the treatment of many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to the survivors of pediatric cancer.i

The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.ii Infants and young children that are affected by ototoxicity at critical stages of development lack speech and language development and literacy, and older children and adolescents often lack social-emotional development and educational achievement.iii

PEDMARK

®

 (sodium thiosulfate injection)

PEDMARK® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. PEDMARK is also recommended for the Adolescent and Young Adult (AYA) population by the National Comprehensive Cancer Network® as a preventative treatment option to reduce hearing loss associated with platinum-based chemotherapy in patients with localized, non-metastatic tumors. PEDMARK is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the first and only therapeutic agent with proven efficacy and safety data with an established dosing regimen, across two open-label, randomized Phase 3 clinical studies, the Children’s Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Indications and Usage

PEDMARK® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use

The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

Important Safety Information

PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.

Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.

PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.

Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.

Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m2.

Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.

The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

Please see full Prescribing Information for PEDMARK® at: www.PEDMARK.com.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.


Forward Looking Statements


Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans respecting PEDMARK
®
, the market opportunity for and market impact of PEDMARK
®
, its potential impact on patients and anticipated benefits associated with its use, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2023. Fennec disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at 

www.sec.gov

 and 

www.sedar.com

.

PEDMARK® and Fennec® are registered trademarks of Fennec Pharmaceuticals Inc.

©2024 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1604-v1

For further information, please contact:

Investors:

Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate and Media:

Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
[email protected]


i Rybak L. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Current Opinion in Otolaryngology & Head and Neck Surgery. 2007, Vol. 15: 364-369.


ii Landier W. Ototoxicity and Cancer Therapy. Cancer. June 2016 Vol. 122, No.11: 1647-1658.


iii Bass JK, Knight KR, Yock TI, et al. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report from the Children’s Oncology Group. Pediatric Blood & Cancer. 2016 Jul;63(7):1152-1162.



Posted on

AngloGold Ashanti plc Announces Board Committee and Board Role Changes

AngloGold Ashanti plc Announces Board Committee and Board Role Changes

LONDON & DENVER & JOHANNESBURG–(BUSINESS WIRE)–
AngloGold Ashanti plc (the “Company”) announces that with effect from 1 January, the membership of its Board Committees will be as follows:

Audit and Risk Committee

Alan Ferguson (Chair)

Kojo Busia

Bruce Cleaver

Rhidwaan Gasant

Al Garner

Jinhee Magie

Diana Sands

Compensation and Human Resources Committee

Al Garner (Chair)

Alan Ferguson

Rhidwaan Gasant

Nicky Newton-King

Diana Sands

Nominations and Governance Committee

Jochen Tilk (Chair)

Rhidwaan Gasant

Alan Ferguson

Al Garner

Diana Sands

Social, Ethics and Sustainability Committee

Bruce Cleaver (Chair)

Kojo Busia

Rhidwaan Gasant

Jinhee Magie

Nicky Newton-King

In addition, Rhidwaan Gasant, Lead Independent Director, has informed the Company that he will not stand for re-appointment at the Company’s Annual General Meeting in May 2025 and will therefore retire as a non-executive director from the conclusion of the meeting.

“On behalf of the Board, I would like to thank Rhidwaan for the significant contribution he has made to AngloGold Ashanti over his tenure as director, and in particular as Lead Independent Director,” said Chairman Jochen Tilk. “We wish him all the very best in his future endeavours.”

The Board of Directors is pleased to appoint Alan Ferguson as Lead Independent Director from this date. Alan Ferguson will step down as the Audit and Risk Committee Chair from the conclusion of the 2025 AGM but will continue to serve as a member of the Committee. Diana Sands will succeed Mr Ferguson as Chair of the Audit and Risk Committee. All appointments are subject to the directors’ re-appointment by shareholders at the next AGM.

JSE Sponsor: The Standard Bank of South Africa Limited

Media

Andrea Maxey

+61 08 9435 4603 / +61 400 072 199

[email protected]

General inquiries

[email protected]

Investors

Andrea Maxey

+61 08 9435 4603 / +61 400 072 199

[email protected]

Yatish Chowthee

+27 11 637 6273 / +27 78 364 2080

[email protected]

Website: www.anglogoldashanti.com

KEYWORDS: South Africa Africa United States United Kingdom North America Europe

INDUSTRY KEYWORDS: Professional Services Natural Resources Mining/Minerals Finance

MEDIA:

Logo
Logo
Posted on

Canoo Inc. Announces 1-for-20 Reverse Stock Split Effective December 24, 2024

JUSTIN, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) — Canoo Inc. (NASDAQ: GOEV), (“Canoo” or the “Company”), an advanced high-tech mobility company, announced today that it will effect a 1-for-20 reverse stock split of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective on December 24, 2024, at 8:00 a.m., Eastern Time (“Effective Date”). Canoo’s Common Stock will continue to trade on The Nasdaq Capital Market under the existing ticker symbol “GOEV” and will begin trading on a split-adjusted basis when the market opens on December 24, 2024. The new CUSIP number for Canoo’s Common Stock following the reverse stock split will be 13803R300.

At the Company’s Annual Meeting of Stockholders held on December 6, 2024 (the “Annual Meeting”), the Company’s stockholders granted the Company’s board of directors (the “Board”) the discretion to effect one or more consolidations of the issued and outstanding shares of the Company’s Common Stock with each reverse stock split ratio ranging from 1:2 up to 1:30 through an amendment to its Second Amended and Restated Certificate of Incorporation; provided that (i) the Company shall not effect reverse stock splits that, in the aggregate, exceed 1:60 and (ii) any reverse stock split is completed prior to the one-year anniversary of the date on which the reverse stock split proposal is approved by the Company’s stockholders. The Board approved a 1-for-20 reverse split ratio, and the Company filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation on December 19, 2024, to effect the reverse stock split.

The Board implemented the reverse stock split with the objective of bringing the Company into compliance with the minimum bid price requirement for maintaining the listing of its Common Stock on Nasdaq, and to make the bid price more attractive to a broader group of institutional and retail investors. Nasdaq requires, among other things, that a listing company’s common stock maintains a minimum bid price of at least $1.00 per share. To evidence compliance with this requirement, the closing bid price of the Company’s Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days by June 2, 2025.

As a result of the reverse stock split, every 20 shares of the Company’s Common Stock will automatically be combined into one share of Common Stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company’s equity, except for immaterial adjustments that may result from the treatment of fractional shares as described below. No fractional shares will be issued in connection with the reverse stock split.

Canoo’s transfer agent, Continental Stock Transfer & Trust Company (“Continental”), will aggregate all fractional shares of our Common Stock and sell them as soon as practicable after the Effective Date at the then-prevailing prices on the open market, on behalf of those stockholders who would otherwise be entitled to receive a fractional share of our Common Stock as a result of the reverse stock split. The Company expects that Continental will conduct the sale in an orderly fashion at a reasonable pace and that it may take several days to sell all the aggregated fractional shares of our Common Stock (the “Aggregated Fractional Shares”). After the completion of such sale, stockholders of record who otherwise would be entitled to receive fractional shares (i.e., stockholders that hold a number of pre-reverse stock split shares of Common Stock not evenly divisible by the final ratio) will instead receive their respective pro rata share of the total proceeds of that sale (the “Total Sale Proceeds”). These stockholders will be entitled to a cash payment (without interest), in lieu of any fractional shares, in an amount equal to: (a) their respective fractional share interest, multiplied by (b) a share price equal to (i) the Total Sale Proceeds, divided by (ii) the Aggregated Fractional Shares. There will not be a reduction in the total number of authorized shares of Common Stock.

As of the Effective Date, the number of shares of Common Stock available for issuance under the Company’s equity incentive plans and issuable pursuant to equity awards immediately prior to the reverse stock split will be proportionately adjusted by the reverse stock split. The exercise prices of the Company’s outstanding options and equity awards will be adjusted in accordance with their respective terms.

The combination of, and reduction in, the number of issued shares of Common Stock as a result of the reverse stock split will occur automatically at the Effective Date without any additional action on the part of our stockholders. Continental is acting as the exchange agent for the reverse stock split and will send stockholders a transaction statement indicating the number of shares of Common Stock stockholders hold after the reverse stock split. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.

Additional information regarding the reverse stock split is available on the Form 8-K filed December 192, 2024, as well as in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 8, 2024, a copy of which is available at www.sec.gov and on the Company’s website. For more information, visit www.canoo.com

About Canoo

Founded in 2017, Canoo Inc. (NASDAQ: GOEV) is an automotive tech company that manufactures electric cargo vehicles, built to deliver, for large commercial, government and fleet customers globally. The company has developed design-forward innovative electric vehicles with steer-by-wire technology on its common modular platform with end-to-end software plus power solutions. Canoo’s platform is purpose-built to maximize the vehicle interior space and is customizable to support a wide range of business and government applications. Headquartered in Justin, Texas, Canoo has teams located in California, Michigan and Oklahoma with world-class vehicle and battery facilities in Oklahoma City. For more information please visitwww.canoo.com and investors.canoo.com.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of the reverse stock split and the effect the reverse stock split will have on the Company’s ability to regain compliance with the Nasdaq Listing standards. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Canoo’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Canoo. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; Canoo’s ability to access future capital, via debt or equity markets, or other sources; the rollout of Canoo’s business and the timing of expected business milestones and commercial launch; future market adoption of Canoo’s offerings; risks related to Canoo’s go-to-market strategy and manufacturing strategy; the effects of competition on Canoo’s future business, and those factors discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Canoo’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2024, as well as its past and future Quarterly Reports on Form 10-Q and other filings with the SEC, copies of which may be obtained by visiting Canoo’s Investors Relations website at investors.canoo.com or the SEC’s website at www.sec.gov. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Canoo does not presently know or that Canoo currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Canoo’s expectations, plans or forecasts of future events and views as of the date of this press release. Canoo anticipates that subsequent events and developments will cause Canoo’s assessments to change.

However, while Canoo may elect to update these forward-looking statements at some point in the future, Canoo specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Canoo’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Media Contact

[email protected]

Investor Relations Contact


[email protected]

Source: Canoo Inc.



Posted on

Joby Successfully Conducts First FAA Testing under TIA, Begins Final Phase of Certification Program

Joby Successfully Conducts First FAA Testing under TIA, Begins Final Phase of Certification Program

  • Type Inspection Authorization is considered the final phase of aircraft certification ahead of commercial service

  • Tests were completed using an FAA-conforming flight deck in a Joby simulator

  • Company targets 2025 to start TIA flight testing with first FAA-conforming aircraft, currently being built

SANTA CRUZ, Calif.–(BUSINESS WIRE)–
Joby Aviation, Inc. (NYSE:JOBY), a company developing electric air taxis for commercial passenger service, today announced it has entered the final phase of certification for its electric air taxi, having conducted its first FAA testing under Type Inspection Authorization (“TIA”). The testing involved pilots from the Federal Aviation Administration (“FAA”) evaluating human factors elements of flight safety using an FAA-conforming flight deck in a Joby simulator.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241220456518/en/

Joby conducted its first testing under TIA on the flight deck of the company’s electric air taxi, with FAA pilots using FAA-conforming hardware in Marina, California. (Photo: Joby Aviation)

Joby conducted its first testing under TIA on the flight deck of the company’s electric air taxi, with FAA pilots using FAA-conforming hardware in Marina, California. (Photo: Joby Aviation)

TIA testing is considered the final phase of the type certification process, which paves the way for an aircraft to begin commercial passenger operations. This phase involves FAA test pilots conducting testing to validate an aircraft’s performance and safety in accordance with previously-approved certification test plans.

“This milestone demonstrates Joby’s continued industry leadership and is a reflection of the maturity of our test program and the rigorous company testing we’ve already completed,” said JoeBen Bevirt, CEO and Founder at Joby Aviation.

“As well as continuing the ‘for credit’ testing of components, aerostructures and systems that is already underway, we are targeting the start of TIA flight testing in 2025 with our first FAA-conforming aircraft, which is currently being built at our facility in Marina, California.”

The tests were conducted according to a set of criteria outlined in an FAA-approved human factors certification test plan and measured pilot workload under various expected flight conditions, physical ergonomics of the flight deck, as well as other human factors aspects of aircraft safety. Four FAA test pilots completed three days of TIA testing during the engagement.

In another major achievement earlier this month, Joby announced it has successfully completed static load testing on a FAA-conforming tail structure of the aircraft, marking the first time the Company had tested a major aerostructure for FAA credit.

Joby is the first eVTOL manufacturer to complete three of five stages of the FAA type certification program and is more than 40 percent complete with the Company’s work for the fourth stage.

Joby’s electric air taxi is designed to carry a pilot and up to four passengers at speeds of up to 200 mph, offering high-speed mobility with a fraction of the noise produced by helicopters and zero operating emissions.

About Joby

Joby Aviation, Inc. (NYSE:JOBY) is a California-based transportation company developing an all-electric, vertical take-off and landing air taxi which it intends to operate as part of a fast, quiet, and convenient service in cities around the world. To learn more, visit www.jobyaviation.com.

Forward Looking Statements

This release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the development and performance of our aircraft, the growth of our manufacturing capabilities, our regulatory outlook, progress and timing, the expected timing of type certification; our business plan, objectives, goals and market opportunity; our current expectations relating to our business, financial condition, results of operations, prospects, capital needs and growth of our operations; and the expected benefits of our vertically-integrated business model, including the ability to rapidly bring new technologies to market. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including: our ability to launch our air taxi service and the growth of the urban air mobility market generally; our ability to produce aircraft that meet our performance expectations in the volumes and on the timelines that we project; the competitive environment in which we operate; our future capital needs; our ability to adequately protect and enforce our intellectual property rights; our ability to effectively respond to evolving regulations and standards relating to our aircraft; our reliance on third-party suppliers and service partners; uncertainties related to our estimates of the size of the market for our service and future revenue opportunities; and other important factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on February 27, 2024, our Quarterly Report on Form 10-Q, filed with the SEC on November 6, 2024, and in future filings and other reports we file with or furnish to the SEC. Any such forward-looking statements represent management’s estimates and beliefs as of the date of this release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Joby Aviation

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Engineering Air Aerospace Transport Manufacturing Transportation Travel

MEDIA:

Logo
Logo
Photo
Photo
Joby conducted its first testing under TIA on the flight deck of the company’s electric air taxi, with FAA pilots using FAA-conforming hardware in Marina, California. (Photo: Joby Aviation)
Posted on

Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility

Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility

State-of-the-art instrument enhances research in structural biology and protein analysis

ZÜRICH–(BUSINESS WIRE)–Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities of several user groups, enabling advanced studies in structural biology and macromolecular analysis. The instrument, located at the University of Zürich, is the second 1.2 GHz NMR in Switzerland, with the first at ETH used for developing solid-state NMR techniques, and studying materials and biological systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241220748125/en/

New 1.2 GHz Avance® at UZH site of the Swiss High-Field NMR Facility (Photo: Business Wire)

New 1.2 GHz Avance® at UZH site of the Swiss High-Field NMR Facility (Photo: Business Wire)

The Swiss High-field NMR Facility has locations at Biozentrum Basel and at University of Zürich. The new 1.2 GHz NMR complements the existing 800 MHz NMR in Basel and other high-field NMRs for protein structure determination, measurement of protein dynamics, ligand binding studies, conformational fingerprinting, and the analysis of protein-protein interactions.

Professor Oliver Zerbe from University of Zürich stated: “The 1.2 GHz NMR enables the study G protein-coupled receptors (GPCRs) in greater detail to define dynamic behavior and conduct drug binding studies. The higher resolution and dispersion at 1.2 GHz enhance the study of interactions of drug candidates with GPCRs. Professor Ricarda Törner, who will join UZH in 2025, will greatly benefit from increased resolution in her studies of intrinsically disordered proteins. Similarly, Professor Sigel’s group anticipates significant advantages for their RNA research.”

Stephan Grzesiek, Professor of Structural Biology at Biozentrum Basel, who started the initiative for a Swiss high-field solution NMR, remarked: “Finally, we also have a highest-field NMR available for Swiss solution NMR. It will enable new NMR methods and explore the limits of detection in disease-relevant applications, such as GPCR signaling and cancer.”

His colleague, Professor Sebastian Hiller from Biozentrum Basel noted: “The 1.2 GHz NMR allows to study structures and dynamics of chaperone-client complexes at atomic resolution. These detailed descriptions will reveal biophysical laws governing chaperone function, with implications for neurodegenerative diseases, such as Parkinson’s.”

Detlef Günther, Professor for Trace Element and Micro Analysis, and Vice President of Research at ETH Zürich (2015-2022) when the instrument was ordered, remarked: “We are excited to provide our scientists with this ultra-high field NMR. This collaboration will enable groundbreaking research in structural biology, furthering our understanding of complex biological systems.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Investor Contact:

Joe Kostka

Director, Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: [email protected]

Media Contact:

Markus Ziegler

Sr. Director and Head of Group Marketing

Bruker BioSpin

T: +49 172 3733531

E: [email protected]

KEYWORDS: Switzerland Europe

INDUSTRY KEYWORDS: Biotechnology Technology Health Pharmaceutical Semiconductor Other Science Research Artificial Intelligence Genetics Science Clinical Trials

MEDIA:

Logo
Logo
Photo
Photo
New 1.2 GHz Avance® at UZH site of the Swiss High-Field NMR Facility (Photo: Business Wire)
Posted on

Marti Announces Election of Alex Spiro to Its Board of Directors

Marti Announces Election of Alex Spiro to Its Board of Directors

Accomplished Corporate Attorney with Significant Experience Advising Innovative Growth Companies Joins Board

ISTANBUL–(BUSINESS WIRE)–
Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye’s leading mobility super app, today announced the election of Alex Spiro to its Board of Directors as a Class II director at the Company’s 2024 annual general meeting of shareholders.

In addition to being a well known litigator and partner at Quinn Emanuel Urquhart & Sullivan LLP, Mr. Spiro serves as Chairman of Glassbridge Enterprises and is a board member and strategic advisor to a number of innovative companies. Mr. Spiro is a former prosecutor and the former director of an autism children’s program at McLean Hospital, Harvard’s psychiatric hospital. Mr. Spiro is a graduate of Harvard Law School, where he continues to teach. He has lectured and written on a variety of subjects related to psychology and the law.

“I am very pleased to have the opportunity to work with Alex on Marti’s Board. His experience with a broad range of clients across the fields of business and politics in the U.S., and, most notably, with leading global technology entrepreneurs, gives me confidence that he will contribute to our Company and mission,” said Marti’s Founder and CEO, Oguz Alper Oktem.

“I have had the good fortune of working with some of the greatest entrepreneurs and companies in the world. Alper and his team are among the best I’ve seen. I am pleased to support them and the Company as we reach scale and achieve profitability in 2025,” said Alex Spiro.

About Marti:

Founded in 2018, Marti is Türkiye’s leading mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti’s offerings are serviced by proprietary software systems and IoT infrastructure. For more information, visit www.marti.tech.

Cautionary Note Regarding Forward-Looking Statements:

Certain statements made in this press release constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements related to the Company’s ability to reach scale and achieve profitability in 2025. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks discussed in the Company’s filings with the SEC, including the Company’s Annual Report on Form 20-F. Marti undertakes no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law.

Investor Contact

Marti Technologies, Inc.

Turgut Yilmaz

[email protected]

KEYWORDS: Turkey Europe

INDUSTRY KEYWORDS: IOT (Internet of Things) Apps/Applications Technology Transport Mobile/Wireless Software Public Transport

MEDIA:

Logo
Logo